Skip to main content
Fig. 1 | Antimicrobial Resistance & Infection Control

Fig. 1

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 1

An overview of flow of each patient’s events. Abbreviations: EOT end-of-treatment visit, LFU late follow-up visit (42–49 days following the initiation of the treatment), TOC test-of-cure visit (28–35 days following the initiation of treatment)

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us